{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:08Z","timestamp":1740107708898,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\/objectives<\/jats:title>\n                <jats:p>To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were randomized to IV golimumab 2 mg\/kg (<jats:italic>n<\/jats:italic>=241) at Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (<jats:italic>n<\/jats:italic>=239) at Weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg\/kg at Weeks 24, 28, then q8w through Week 52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) was assessed. Relationships between these outcomes and disease activity and patient functional capability were evaluated post hoc.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At Week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (\u22122.91 vs \u22120.71), and WLQ productivity loss score (\u22122.92 vs \u22120.78) was greater in the golimumab group versus the placebo group, respectively. At Week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: \u22122.89 and \u22123.31; WLQ productivity loss: \u22124.49 and \u22123.28, respectively). HRQoL and productivity were generally associated with disease activity and functional capability, with continued association from Week 8 through Week 52.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year<\/jats:italic>\u2022 <jats:italic>Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes<\/jats:italic>\u2022 <jats:italic>IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05639-1","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T22:02:44Z","timestamp":1614722564000},"page":"3667-3677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Hung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilianne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"5639_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","volume":"22","author":"DD Gladman","year":"2009","unstructured":"Gladman DD (2009) Psoriatic arthritis. Dermatol Ther 22:40\u201355","journal-title":"Dermatol Ther"},{"key":"5639_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351\u2013360","journal-title":"Semin Arthritis Rheum"},{"key":"5639_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT (2016) Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther 3:91\u2013102","journal-title":"Rheumatol Ther"},{"key":"5639_CR4","first-page":"342","volume":"32","author":"M Kennedy","year":"2014","unstructured":"Kennedy M, Papneja A, Thavaneswaran A, Chandran V, Gladman DD (2014) Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis. Clin Exp Rheumatol 32:342\u2013348","journal-title":"Clin Exp Rheumatol"},{"key":"5639_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","volume":"6","author":"JF Merola","year":"2019","unstructured":"Merola JF, Shrom D, Eaton J, Dworkin C, Krebsbach C, Shah-Manek B, Birt J (2019) Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther 6:33\u201345","journal-title":"Rheumatol Ther"},{"key":"5639_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2012","unstructured":"Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD (2012) Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 51:571\u2013576","journal-title":"Rheumatology"},{"key":"5639_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Duffin KC, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673\u2013680","journal-title":"Ann Rheum Dis"},{"key":"5639_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3899\/jrheum.170874","volume":"45","author":"N Iragorri","year":"2018","unstructured":"Iragorri N, Hofmeister M, Spackman E, Hazlewood GS (2018) The effect of biologic and targeted synthetic drugs on work- and productivity-related outcomes for patients with psoriatic arthritis: a systematic review. J Rheumatol 45:1124\u20131130","journal-title":"J Rheumatol"},{"key":"5639_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/art.21177","volume":"53","author":"JA Husted","year":"2005","unstructured":"Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD (2005) Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 53:404\u2013409","journal-title":"Arthritis Rheum"},{"key":"5639_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3899\/jrheum.140259","volume":"41","author":"JA Walsh","year":"2014","unstructured":"Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014) Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol 41:1670\u20131674","journal-title":"J Rheumatol"},{"key":"5639_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","volume":"51","author":"W Tillett","year":"2012","unstructured":"Tillett W, de-Vries C, McHugh NJ (2012) Work disability in psoriatic arthritis: a systematic review. Rheumatology 51:275\u2013283","journal-title":"Rheumatology"},{"key":"5639_CR12","doi-asserted-by":"publisher","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B (2012) Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 7:e52935","journal-title":"PLoS One"},{"key":"5639_CR13","doi-asserted-by":"crossref","unstructured":"Walsh J, Ogdie A, Michaud K, Peterson S, Holdsworth E, Karyekar C, Booth N, Kemp J, Chakravarty S, Kafka S, Gossec L (2019) Enthesitis, dactylitis, and axial disease in psoriatic arthritis (PsA): impact on patient quality of life and work productivity [abstract]. Arthritis Rheum 71(suppl 10) https:\/\/acrabstracts.org\/abstract\/enthesitis-dactylitis-and-axial-disease-in-psoriatic-arthritis-psa-impact-on-patient-quality-of-life-and-work-productivity\/. Accessed 4\u00a0Oct\u00a02019","DOI":"10.1136\/annrheumdis-2019-eular.7428"},{"key":"5639_CR14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheum 69:2151\u20132161","journal-title":"Arthritis Rheum"},{"key":"5639_CR15","doi-asserted-by":"crossref","unstructured":"Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2020) Efficacy and safety of intravenous golimumab through 1 year in patients with active psoriatic arthritis. Arthritis Care Res (Hoboken) 72:806\u2013813.","DOI":"10.1002\/acr.23905"},{"key":"5639_CR16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jval.2020.06.007","volume":"23","author":"ME Husni","year":"2020","unstructured":"Husni ME, Kavanaugh A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Harrison DD, Han C (2020) Effects of intravenous golimumab on health-related quality of life in patients with psoriatic arthritis: 24-week results of the GO-VIBRANT trial. Value Health 23:1286\u20131291","journal-title":"Value Health"},{"key":"5639_CR17","doi-asserted-by":"publisher","unstructured":"Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A (2020) The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-05342-7 [Epub ahead of print]","DOI":"10.1007\/s10067-020-05342-7"},{"key":"5639_CR18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"5639_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"5639_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203\u2013220","journal-title":"Med Care"},{"key":"5639_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708\u2013715","journal-title":"Value Health"},{"key":"5639_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00005650-200101000-00009","volume":"39","author":"D Lerner","year":"2001","unstructured":"Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D (2001) The work limitations questionnaire. Med Care 39:72\u201385","journal-title":"Med Care"},{"key":"5639_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"issue":"Suppl 85","key":"5639_CR24","first-page":"S65","volume":"32","author":"PLCM van Riel","year":"2014","unstructured":"van Riel PLCM (2014) The development of the disease activity score (DAS) and the disease active score using 28 joint counts (DAS28). Clin Exp Rheumatol 32(Suppl 85):S65\u2013S74","journal-title":"Clin Exp Rheumatol"},{"key":"5639_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441\u20131447","journal-title":"Ann Rheum Dis"},{"key":"5639_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"5639_CR27","doi-asserted-by":"crossref","unstructured":"Ware JE Jr (2000) SF-36 health survey update. Spine (Phila Pa 1976) 25:3130\u20133139","DOI":"10.1097\/00007632-200012150-00008"},{"key":"5639_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, Botteman M, Busschbach J (2017) Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health 20:18\u201327","journal-title":"Value Health"},{"key":"5639_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4236\/ojs.2015.57075","volume":"5","author":"MO Akinwande","year":"2015","unstructured":"Akinwande MO, Dikko HG, Samson A (2015) Variance inflation factor: as a condition for the inclusion of suppressor variable(s) in regression analysis. Open J Stat 5:754\u2013767","journal-title":"Open J Stat"},{"key":"5639_CR30","first-page":"603","volume":"56","author":"W Tillett","year":"2017","unstructured":"Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N (2017) Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicenter observational cohort study of psoriatic arthritis. Rheumatology 56:603\u2013612","journal-title":"Rheumatology"},{"key":"5639_CR31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","volume":"26","author":"R Gniadecki","year":"2012","unstructured":"Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS (2012) Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 26:1436\u20131443","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5639_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV (2019) United States valuation of EQ-5D-5L health states using an international protocol. Value Health 22:931\u2013941","journal-title":"Value Health"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05639-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:10:01Z","timestamp":1628673001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05639-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5639"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05639-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexis Ogdie has received consulting fees from Amgen, AbbVie Pharmaceuticals Inc., Bristol-Myers Squibb, Celgene, Corrona, Janssen, Eli Lilly and Company, Novartis, and Pfizer and has received grant support from Pfizer and Novartis (to University of Pennsylvania) and Amgen (to Forward Databank of which Dr. Ogdie is the principal investigator). Dr. Ogdie\u2019s husband has received royalties from Novartis. Jessica A. Walsh has received research grants or served as a consultant for AbbVie Pharmaceuticals Inc., Pfizer, Janssen, Eli Lilly and Company, Novartis, and UCB. Soumya D. Chakravarty is an employee of Janssen Scientific Affairs, LLC and owns stock in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. Steven Peterson, Nan Li, and Eric K.H. Chan are employees of Janssen Global Services, LLC and own stock in Johnson & Johnson, of which Janssen Global Services, LLC is a wholly owned subsidiary. Kim Hung Lo, Lilianne Kim, and Elizabeth C. Hsia are employees of Janssen Research & Development, LLC and own stock in Johnson & Johnson, of which Janssen Research & Development is a wholly owned subsidiary. Arthur Kavanaugh received grants from and\/or served as a consultant for Amgen, Celgene, Eli Lilly and Company, Janssen, Pfizer, and UCB. M. Elaine Husni has served as a consultant for AbbVie Pharmaceuticals Inc., Amgen, Bristol-Meyers Squibb, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, Regeneron Pharmaceuticals, and UCB. The authors have full control of all primary data and agree to allow the journal to review the data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}